|
|
Office Locations:
|
479 Jessie St
San Francisco, CA 94103
| | |
|
|
|
|
|
Consumer Products & Services
Food & Agriculture
Life Sciences & Healthcare
|
|
|
|
IndieBio is the world's first startup accelerator for synthetic biology. Twice a year, fifteen early stage biology companies move to downtown San Francisco to take part in their intense four-month program. Each team receives seed funding, lab and co-working space, dedicated mentorship, and becomes part of a network of IndieBio alumni, investors, biotech entrepreneurs, investors, press, and corporate partners. The investment is broken into two parts. The first is a share purchase agreement of 8% for taking part in the program and a $250,000 investment (Accelerator Contract for Equity ('ACE')) at $3 million dollar valuation cap for a total package valued at $250k ($200k in Cash) in funding. Over 200 companies were born and built with IndieBio.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
